nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—Triamcinolone—multiple sclerosis	0.215	0.424	CbGbCtD
Clodronate—PTGS2—Betamethasone—multiple sclerosis	0.184	0.364	CbGbCtD
Clodronate—PTGS2—Dexamethasone—multiple sclerosis	0.107	0.212	CbGbCtD
Clodronate—SLC25A4—peripheral nervous system—multiple sclerosis	0.0284	0.166	CbGeAlD
Clodronate—SLC25A6—Influenza Virus Induced Apoptosis—TGFB1—multiple sclerosis	0.0177	0.139	CbGpPWpGaD
Clodronate—Acute myeloid leukaemia—Azathioprine—multiple sclerosis	0.0131	0.0708	CcSEcCtD
Clodronate—SLC25A6—brainstem—multiple sclerosis	0.0116	0.0683	CbGeAlD
Clodronate—SLC25A4—retina—multiple sclerosis	0.00916	0.0537	CbGeAlD
Clodronate—SLC25A6—Host Interactions with Influenza Factors—TGFB1—multiple sclerosis	0.0085	0.0668	CbGpPWpGaD
Clodronate—PTGS2—leg—multiple sclerosis	0.00818	0.048	CbGeAlD
Clodronate—Acute leukaemia—Azathioprine—multiple sclerosis	0.00752	0.0407	CcSEcCtD
Clodronate—SLC25A6—spinal cord—multiple sclerosis	0.00724	0.0425	CbGeAlD
Clodronate—SLC25A5—medulla oblongata—multiple sclerosis	0.00706	0.0414	CbGeAlD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.00668	0.0525	CbGpPWpGaD
Clodronate—SLC25A4—medulla oblongata—multiple sclerosis	0.00662	0.0388	CbGeAlD
Clodronate—SLC25A5—midbrain—multiple sclerosis	0.00646	0.0379	CbGeAlD
Clodronate—SLC25A5—spinal cord—multiple sclerosis	0.0063	0.0369	CbGeAlD
Clodronate—SLC25A6—nervous system—multiple sclerosis	0.0061	0.0358	CbGeAlD
Clodronate—SLC25A4—midbrain—multiple sclerosis	0.00605	0.0355	CbGeAlD
Clodronate—SLC25A5—Azacitidine—Cladribine—multiple sclerosis	0.00599	0.528	CbGdCrCtD
Clodronate—SLC25A4—spinal cord—multiple sclerosis	0.0059	0.0346	CbGeAlD
Clodronate—SLC25A6—central nervous system—multiple sclerosis	0.00587	0.0345	CbGeAlD
Clodronate—SLC25A6—cerebellum—multiple sclerosis	0.00574	0.0337	CbGeAlD
Clodronate—SLC25A5—nervous system—multiple sclerosis	0.00531	0.0311	CbGeAlD
Clodronate—SLC25A5—central nervous system—multiple sclerosis	0.00511	0.03	CbGeAlD
Clodronate—Hyperphosphataemia—Mitoxantrone—multiple sclerosis	0.00509	0.0275	CcSEcCtD
Clodronate—SLC25A5—cerebellum—multiple sclerosis	0.005	0.0293	CbGeAlD
Clodronate—SLC25A4—nervous system—multiple sclerosis	0.00497	0.0292	CbGeAlD
Clodronate—SLC25A4—central nervous system—multiple sclerosis	0.00479	0.0281	CbGeAlD
Clodronate—SLC25A4—cerebellum—multiple sclerosis	0.00468	0.0275	CbGeAlD
Clodronate—SLC25A6—brain—multiple sclerosis	0.00466	0.0274	CbGeAlD
Clodronate—Stomach ache—Mitoxantrone—multiple sclerosis	0.00409	0.0221	CcSEcCtD
Clodronate—SLC25A5—brain—multiple sclerosis	0.00406	0.0238	CbGeAlD
Clodronate—SLC25A4—brain—multiple sclerosis	0.0038	0.0223	CbGeAlD
Clodronate—PTGS2—S1P1 pathway—S1PR1—multiple sclerosis	0.00327	0.0257	CbGpPWpGaD
Clodronate—Local reaction—Mitoxantrone—multiple sclerosis	0.00314	0.017	CcSEcCtD
Clodronate—Neoplasm malignant—Cladribine—multiple sclerosis	0.0031	0.0167	CcSEcCtD
Clodronate—Extravasation—Cladribine—multiple sclerosis	0.00303	0.0164	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Fingolimod—multiple sclerosis	0.00299	0.0161	CcSEcCtD
Clodronate—Serum creatinine increased—Mitoxantrone—multiple sclerosis	0.00283	0.0153	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.00277	0.0218	CbGpPWpGaD
Clodronate—SLC25A6—Influenza Infection—RPL5—multiple sclerosis	0.00269	0.0212	CbGpPWpGaD
Clodronate—SLC25A5—Host Interactions of HIV factors—CD28—multiple sclerosis	0.00269	0.0211	CbGpPWpGaD
Clodronate—Pneumonia—Fingolimod—multiple sclerosis	0.00262	0.0142	CcSEcCtD
Clodronate—Wheezing—Cladribine—multiple sclerosis	0.00257	0.0139	CcSEcCtD
Clodronate—Neoplasm malignant—Azathioprine—multiple sclerosis	0.00252	0.0136	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTPRK—multiple sclerosis	0.00249	0.0195	CbGpPWpGaD
Clodronate—Connective tissue disorder—Fingolimod—multiple sclerosis	0.0023	0.0124	CcSEcCtD
Clodronate—SLC25A6—Host Interactions of HIV factors—CD28—multiple sclerosis	0.00225	0.0177	CbGpPWpGaD
Clodronate—Hepatocellular injury—Azathioprine—multiple sclerosis	0.00215	0.0116	CcSEcCtD
Clodronate—Mediastinal disorder—Fingolimod—multiple sclerosis	0.00211	0.0114	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.0021	0.0165	CbGpPWpGaD
Clodronate—Renal failure acute—Cladribine—multiple sclerosis	0.00208	0.0112	CcSEcCtD
Clodronate—Renal impairment—Cladribine—multiple sclerosis	0.00202	0.0109	CcSEcCtD
Clodronate—Extravasation—Mitoxantrone—multiple sclerosis	0.00199	0.0108	CcSEcCtD
Clodronate—Proteinuria—Mitoxantrone—multiple sclerosis	0.00198	0.0107	CcSEcCtD
Clodronate—Cardiac failure—Cladribine—multiple sclerosis	0.00197	0.0106	CcSEcCtD
Clodronate—Protein urine present—Mitoxantrone—multiple sclerosis	0.00195	0.0105	CcSEcCtD
Clodronate—Hypocalcaemia—Mitoxantrone—multiple sclerosis	0.0019	0.0103	CcSEcCtD
Clodronate—Hypercalcaemia—Methylprednisolone—multiple sclerosis	0.00188	0.0102	CcSEcCtD
Clodronate—Hepatic function abnormal—Azathioprine—multiple sclerosis	0.00179	0.00966	CcSEcCtD
Clodronate—SLC25A4—Host Interactions of HIV factors—CD28—multiple sclerosis	0.00176	0.0138	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—CD28—multiple sclerosis	0.00175	0.0137	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00172	0.00932	CcSEcCtD
Clodronate—SLC25A5—Host Interactions of HIV factors—HLA-A—multiple sclerosis	0.00166	0.013	CbGpPWpGaD
Clodronate—Infection—Fingolimod—multiple sclerosis	0.00165	0.00894	CcSEcCtD
Clodronate—Skin disorder—Fingolimod—multiple sclerosis	0.00162	0.00874	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TBX21—multiple sclerosis	0.0016	0.0126	CbGpPWpGaD
Clodronate—Pneumonia—Cladribine—multiple sclerosis	0.00149	0.00804	CcSEcCtD
Clodronate—Dyspnoea—Fingolimod—multiple sclerosis	0.00148	0.00802	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—CD28—multiple sclerosis	0.00146	0.0115	CbGpPWpGaD
Clodronate—Renal failure—Cladribine—multiple sclerosis	0.00145	0.00786	CcSEcCtD
Clodronate—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00144	0.00777	CcSEcCtD
Clodronate—SLC25A6—Host Interactions of HIV factors—HLA-A—multiple sclerosis	0.00139	0.0109	CbGpPWpGaD
Clodronate—Renal failure acute—Mitoxantrone—multiple sclerosis	0.00137	0.00739	CcSEcCtD
Clodronate—Extravasation—Dexamethasone—multiple sclerosis	0.00136	0.00737	CcSEcCtD
Clodronate—Extravasation—Betamethasone—multiple sclerosis	0.00136	0.00737	CcSEcCtD
Clodronate—PTGS2—medulla oblongata—multiple sclerosis	0.00133	0.0078	CbGeAlD
Clodronate—Pharyngitis—Cladribine—multiple sclerosis	0.00132	0.00713	CcSEcCtD
Clodronate—Urinary tract disorder—Cladribine—multiple sclerosis	0.00131	0.00709	CcSEcCtD
Clodronate—Connective tissue disorder—Cladribine—multiple sclerosis	0.0013	0.00706	CcSEcCtD
Clodronate—Urethral disorder—Cladribine—multiple sclerosis	0.0013	0.00704	CcSEcCtD
Clodronate—Cardiac failure—Mitoxantrone—multiple sclerosis	0.00129	0.00699	CcSEcCtD
Clodronate—Wheezing—Triamcinolone—multiple sclerosis	0.00127	0.00689	CcSEcCtD
Clodronate—Liver disorder—Methotrexate—multiple sclerosis	0.00127	0.00687	CcSEcCtD
Clodronate—PTGS2—midbrain—multiple sclerosis	0.00122	0.00713	CbGeAlD
Clodronate—Pneumonia—Azathioprine—multiple sclerosis	0.00121	0.00654	CcSEcCtD
Clodronate—Mediastinal disorder—Cladribine—multiple sclerosis	0.0012	0.00647	CcSEcCtD
Clodronate—PTGS2—spinal cord—multiple sclerosis	0.00119	0.00696	CbGeAlD
Clodronate—Blood creatinine increased—Mitoxantrone—multiple sclerosis	0.00118	0.00639	CcSEcCtD
Clodronate—Pruritus—Fingolimod—multiple sclerosis	0.00118	0.00637	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CBLB—multiple sclerosis	0.00118	0.00924	CbGpPWpGaD
Clodronate—Dehydration—Mitoxantrone—multiple sclerosis	0.00117	0.00634	CcSEcCtD
Clodronate—Abdominal pain upper—Mitoxantrone—multiple sclerosis	0.00115	0.00623	CcSEcCtD
Clodronate—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	0.00115	0.00901	CbGpPWpGaD
Clodronate—SLC25A4—HIV Infection—CD28—multiple sclerosis	0.00114	0.00899	CbGpPWpGaD
Clodronate—Diarrhoea—Fingolimod—multiple sclerosis	0.00114	0.00616	CcSEcCtD
Clodronate—SLC25A5—Metabolism—SRM—multiple sclerosis	0.00112	0.00879	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.00111	0.00602	CcSEcCtD
Clodronate—SLC25A5—HIV Infection—CCR5—multiple sclerosis	0.00111	0.00869	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.00109	0.00854	CbGpPWpGaD
Clodronate—SLC25A4—Host Interactions of HIV factors—HLA-A—multiple sclerosis	0.00109	0.00853	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—HLA-A—multiple sclerosis	0.00108	0.00847	CbGpPWpGaD
Clodronate—SLC25A5—Host Interactions of HIV factors—CD4—multiple sclerosis	0.00107	0.0084	CbGpPWpGaD
Clodronate—Anaemia—Cladribine—multiple sclerosis	0.00107	0.00578	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—SLC30A7—multiple sclerosis	0.00105	0.00821	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.00104	0.00816	CbGpPWpGaD
Clodronate—PTGS2—nervous system—multiple sclerosis	0.001	0.00586	CbGeAlD
Clodronate—Extravasation—Methotrexate—multiple sclerosis	0.000992	0.00537	CcSEcCtD
Clodronate—Proteinuria—Methotrexate—multiple sclerosis	0.000985	0.00533	CcSEcCtD
Clodronate—Pneumonia—Mitoxantrone—multiple sclerosis	0.000978	0.00529	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000977	0.00528	CcSEcCtD
Clodronate—Cardiac failure—Methylprednisolone—multiple sclerosis	0.000973	0.00526	CcSEcCtD
Clodronate—Mediastinal disorder—Azathioprine—multiple sclerosis	0.000973	0.00526	CcSEcCtD
Clodronate—Protein urine present—Methotrexate—multiple sclerosis	0.000972	0.00526	CcSEcCtD
Clodronate—PTGS2—central nervous system—multiple sclerosis	0.000962	0.00564	CbGeAlD
Clodronate—Renal failure—Mitoxantrone—multiple sclerosis	0.000956	0.00517	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—multiple sclerosis	0.000953	0.00749	CbGpPWpGaD
Clodronate—PTGS2—cerebellum—multiple sclerosis	0.000941	0.00552	CbGeAlD
Clodronate—Oliguria—Methotrexate—multiple sclerosis	0.000939	0.00508	CcSEcCtD
Clodronate—SLC25A6—Metabolism—SRM—multiple sclerosis	0.000938	0.00737	CbGpPWpGaD
Clodronate—Infection—Cladribine—multiple sclerosis	0.000937	0.00507	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—CCR5—multiple sclerosis	0.000927	0.00728	CbGpPWpGaD
Clodronate—Skin disorder—Cladribine—multiple sclerosis	0.000916	0.00495	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—HLA-A—multiple sclerosis	0.000903	0.0071	CbGpPWpGaD
Clodronate—Anorexia—Cladribine—multiple sclerosis	0.000899	0.00486	CcSEcCtD
Clodronate—SLC25A6—Host Interactions of HIV factors—CD4—multiple sclerosis	0.000896	0.00704	CbGpPWpGaD
Clodronate—Cardiac failure—Dexamethasone—multiple sclerosis	0.000885	0.00479	CcSEcCtD
Clodronate—Cardiac failure—Betamethasone—multiple sclerosis	0.000885	0.00479	CcSEcCtD
Clodronate—Anaemia—Azathioprine—multiple sclerosis	0.000869	0.0047	CcSEcCtD
Clodronate—Pharyngitis—Mitoxantrone—multiple sclerosis	0.000866	0.00468	CcSEcCtD
Clodronate—SLC25A5—Disease—GPC5—multiple sclerosis	0.000861	0.00677	CbGpPWpGaD
Clodronate—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.00085	0.075	CbGdCrCtD
Clodronate—SLC25A6—Metabolism of proteins—PABPC1—multiple sclerosis	0.000845	0.00664	CbGpPWpGaD
Clodronate—Dyspnoea—Cladribine—multiple sclerosis	0.000841	0.00455	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000837	0.00453	CcSEcCtD
Clodronate—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000837	0.0738	CbGdCrCtD
Clodronate—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000837	0.0738	CbGdCrCtD
Clodronate—Decreased appetite—Cladribine—multiple sclerosis	0.00082	0.00443	CcSEcCtD
Clodronate—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000818	0.0721	CbGdCrCtD
Clodronate—SLC25A4—Metabolism of proteins—SLC30A7—multiple sclerosis	0.000816	0.00641	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000814	0.0044	CcSEcCtD
Clodronate—Bronchospasm—Methylprednisolone—multiple sclerosis	0.000807	0.00437	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000794	0.0043	CcSEcCtD
Clodronate—SLC25A5—Metabolism—CYP27B1—multiple sclerosis	0.000789	0.0062	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CYP24A1—multiple sclerosis	0.000789	0.0062	CbGpPWpGaD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—multiple sclerosis	0.000788	0.0062	CbGpPWpGaD
Clodronate—Cardiac failure—Prednisone—multiple sclerosis	0.000771	0.00417	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—multiple sclerosis	0.000767	0.00603	CbGpPWpGaD
Clodronate—PTGS2—brain—multiple sclerosis	0.000764	0.00448	CbGeAlD
Clodronate—SLC25A6—Metabolism of proteins—RPL5—multiple sclerosis	0.000762	0.00599	CbGpPWpGaD
Clodronate—Infection—Azathioprine—multiple sclerosis	0.000762	0.00412	CcSEcCtD
Clodronate—Urticaria—Cladribine—multiple sclerosis	0.000749	0.00405	CcSEcCtD
Clodronate—Abdominal pain—Cladribine—multiple sclerosis	0.000746	0.00403	CcSEcCtD
Clodronate—Skin disorder—Azathioprine—multiple sclerosis	0.000745	0.00403	CcSEcCtD
Clodronate—SLC25A4—Metabolism—SRM—multiple sclerosis	0.000732	0.00575	CbGpPWpGaD
Clodronate—SLC25A4—HIV Infection—CCR5—multiple sclerosis	0.000724	0.00569	CbGpPWpGaD
Clodronate—SLC25A6—Disease—GPC5—multiple sclerosis	0.000722	0.00567	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—GPC5—multiple sclerosis	0.000721	0.00567	CbGpPWpGaD
Clodronate—SLC25A4—HIV Infection—HLA-A—multiple sclerosis	0.000705	0.00554	CbGpPWpGaD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—multiple sclerosis	0.000703	0.00552	CbGpPWpGaD
Clodronate—Anaemia—Mitoxantrone—multiple sclerosis	0.000702	0.0038	CcSEcCtD
Clodronate—SLC25A4—Host Interactions of HIV factors—CD4—multiple sclerosis	0.000699	0.0055	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—CD4—multiple sclerosis	0.000695	0.00546	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MBP—multiple sclerosis	0.000685	0.00539	CbGpPWpGaD
Clodronate—Renal failure acute—Methotrexate—multiple sclerosis	0.000681	0.00368	CcSEcCtD
Clodronate—Pruritus—Cladribine—multiple sclerosis	0.000667	0.00361	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000663	0.00359	CcSEcCtD
Clodronate—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000662	0.00358	CcSEcCtD
Clodronate—SLC25A6—Metabolism—CYP27B1—multiple sclerosis	0.000661	0.00519	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—CYP24A1—multiple sclerosis	0.000661	0.00519	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—PABPC1—multiple sclerosis	0.00066	0.00519	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—multiple sclerosis	0.000656	0.00515	CbGpPWpGaD
Clodronate—Pharyngitis—Triamcinolone—multiple sclerosis	0.000653	0.00353	CcSEcCtD
Clodronate—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000646	0.00349	CcSEcCtD
Clodronate—Diarrhoea—Cladribine—multiple sclerosis	0.000645	0.00349	CcSEcCtD
Clodronate—Infection—Mitoxantrone—multiple sclerosis	0.000616	0.00333	CcSEcCtD
Clodronate—Abdominal pain—Azathioprine—multiple sclerosis	0.000606	0.00328	CcSEcCtD
Clodronate—SLC25A6—Metabolism—GPC5—multiple sclerosis	0.000604	0.00475	CbGpPWpGaD
Clodronate—Skin disorder—Mitoxantrone—multiple sclerosis	0.000602	0.00326	CcSEcCtD
Clodronate—Vomiting—Cladribine—multiple sclerosis	0.0006	0.00324	CcSEcCtD
Clodronate—SLC25A5—Metabolism—RRM1—multiple sclerosis	0.000598	0.0047	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—RPL5—multiple sclerosis	0.000595	0.00468	CbGpPWpGaD
Clodronate—Rash—Cladribine—multiple sclerosis	0.000595	0.00322	CcSEcCtD
Clodronate—Dermatitis—Cladribine—multiple sclerosis	0.000594	0.00321	CcSEcCtD
Clodronate—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000592	0.0032	CcSEcCtD
Clodronate—Anorexia—Mitoxantrone—multiple sclerosis	0.000591	0.0032	CcSEcCtD
Clodronate—SLC25A6—Influenza Infection—TGFB1—multiple sclerosis	0.000588	0.00462	CbGpPWpGaD
Clodronate—SLC25A6—HIV Infection—CD4—multiple sclerosis	0.000582	0.00457	CbGpPWpGaD
Clodronate—Angioedema—Prednisolone—multiple sclerosis	0.000569	0.00308	CcSEcCtD
Clodronate—SLC25A4—Disease—GPC5—multiple sclerosis	0.000563	0.00443	CbGpPWpGaD
Clodronate—Nausea—Cladribine—multiple sclerosis	0.00056	0.00303	CcSEcCtD
Clodronate—SLC25A5—Disease—RPL5—multiple sclerosis	0.00056	0.0044	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—BCHE—multiple sclerosis	0.000558	0.00439	CbGpPWpGaD
Clodronate—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000553	0.00299	CcSEcCtD
Clodronate—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000546	0.00295	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000544	0.00428	CbGpPWpGaD
Clodronate—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000539	0.00291	CcSEcCtD
Clodronate—SLC25A5—Disease—SLC11A1—multiple sclerosis	0.000536	0.00421	CbGpPWpGaD
Clodronate—Diarrhoea—Azathioprine—multiple sclerosis	0.000525	0.00284	CcSEcCtD
Clodronate—Angioedema—Triamcinolone—multiple sclerosis	0.000524	0.00283	CcSEcCtD
Clodronate—Angioedema—Methylprednisolone—multiple sclerosis	0.000523	0.00283	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—AQP4—multiple sclerosis	0.000519	0.00408	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CYP27B1—multiple sclerosis	0.000516	0.00405	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CYP24A1—multiple sclerosis	0.000516	0.00405	CbGpPWpGaD
Clodronate—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000513	0.0452	CbGdCrCtD
Clodronate—Connective tissue disorder—Prednisone—multiple sclerosis	0.000511	0.00276	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—multiple sclerosis	0.00051	0.00401	CbGpPWpGaD
Clodronate—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000505	0.0445	CbGdCrCtD
Clodronate—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000505	0.0445	CbGdCrCtD
Clodronate—SLC25A6—Metabolism—RRM1—multiple sclerosis	0.000501	0.00394	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—multiple sclerosis	0.000496	0.0039	CbGpPWpGaD
Clodronate—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000493	0.0435	CbGdCrCtD
Clodronate—Urticaria—Mitoxantrone—multiple sclerosis	0.000493	0.00266	CcSEcCtD
Clodronate—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00049	0.00265	CcSEcCtD
Clodronate—Vomiting—Azathioprine—multiple sclerosis	0.000488	0.00264	CcSEcCtD
Clodronate—Pneumonia—Methotrexate—multiple sclerosis	0.000487	0.00263	CcSEcCtD
Clodronate—Rash—Azathioprine—multiple sclerosis	0.000484	0.00262	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000483	0.00261	CcSEcCtD
Clodronate—Dermatitis—Azathioprine—multiple sclerosis	0.000483	0.00261	CcSEcCtD
Clodronate—Renal failure—Methotrexate—multiple sclerosis	0.000476	0.00257	CcSEcCtD
Clodronate—Angioedema—Dexamethasone—multiple sclerosis	0.000475	0.00257	CcSEcCtD
Clodronate—Angioedema—Betamethasone—multiple sclerosis	0.000475	0.00257	CcSEcCtD
Clodronate—SLC25A4—Metabolism—GPC5—multiple sclerosis	0.000472	0.00371	CbGpPWpGaD
Clodronate—SLC25A6—Disease—RPL5—multiple sclerosis	0.000469	0.00369	CbGpPWpGaD
Clodronate—Infection—Triamcinolone—multiple sclerosis	0.000465	0.00251	CcSEcCtD
Clodronate—Infection—Methylprednisolone—multiple sclerosis	0.000464	0.00251	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—multiple sclerosis	0.000464	0.00364	CbGpPWpGaD
Clodronate—Nausea—Azathioprine—multiple sclerosis	0.000456	0.00246	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—multiple sclerosis	0.000455	0.00357	CbGpPWpGaD
Clodronate—SLC25A4—HIV Infection—CD4—multiple sclerosis	0.000454	0.00357	CbGpPWpGaD
Clodronate—Skin disorder—Methylprednisolone—multiple sclerosis	0.000453	0.00245	CcSEcCtD
Clodronate—SLC25A6—Disease—SLC11A1—multiple sclerosis	0.000449	0.00353	CbGpPWpGaD
Clodronate—PTGS2—S1P1 pathway—MAPK1—multiple sclerosis	0.000442	0.00347	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—BCHE—multiple sclerosis	0.000436	0.00342	CbGpPWpGaD
Clodronate—Pharyngitis—Methotrexate—multiple sclerosis	0.000432	0.00233	CcSEcCtD
Clodronate—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000429	0.00232	CcSEcCtD
Clodronate—SLC25A5—Disease—CD28—multiple sclerosis	0.000428	0.00337	CbGpPWpGaD
Clodronate—Urethral disorder—Methotrexate—multiple sclerosis	0.000426	0.00231	CcSEcCtD
Clodronate—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000424	0.00229	CcSEcCtD
Clodronate—Infection—Betamethasone—multiple sclerosis	0.000422	0.00228	CcSEcCtD
Clodronate—Infection—Dexamethasone—multiple sclerosis	0.000422	0.00228	CcSEcCtD
Clodronate—PTGS2—Overview of nanoparticle effects—TNF—multiple sclerosis	0.000421	0.00331	CbGpPWpGaD
Clodronate—Anaemia—Prednisone—multiple sclerosis	0.000419	0.00226	CcSEcCtD
Clodronate—Dyspnoea—Triamcinolone—multiple sclerosis	0.000417	0.00226	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000416	0.00327	CbGpPWpGaD
Clodronate—Angioedema—Prednisone—multiple sclerosis	0.000414	0.00224	CcSEcCtD
Clodronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—multiple sclerosis	0.000412	0.00324	CbGpPWpGaD
Clodronate—Dyspepsia—Triamcinolone—multiple sclerosis	0.000412	0.00223	CcSEcCtD
Clodronate—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000411	0.00222	CcSEcCtD
Clodronate—Anorexia—Betamethasone—multiple sclerosis	0.000405	0.00219	CcSEcCtD
Clodronate—Anorexia—Dexamethasone—multiple sclerosis	0.000405	0.00219	CcSEcCtD
Clodronate—Urticaria—Prednisolone—multiple sclerosis	0.000404	0.00219	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—TNF—multiple sclerosis	0.000395	0.0031	CbGpPWpGaD
Clodronate—Vomiting—Mitoxantrone—multiple sclerosis	0.000394	0.00213	CcSEcCtD
Clodronate—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000392	0.00212	CcSEcCtD
Clodronate—SLC25A4—Metabolism—RRM1—multiple sclerosis	0.000391	0.00307	CbGpPWpGaD
Clodronate—Rash—Mitoxantrone—multiple sclerosis	0.000391	0.00211	CcSEcCtD
Clodronate—Dermatitis—Mitoxantrone—multiple sclerosis	0.000391	0.00211	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000383	0.00207	CcSEcCtD
Clodronate—Dyspepsia—Betamethasone—multiple sclerosis	0.000374	0.00202	CcSEcCtD
Clodronate—Dyspepsia—Dexamethasone—multiple sclerosis	0.000374	0.00202	CcSEcCtD
Clodronate—Urticaria—Triamcinolone—multiple sclerosis	0.000372	0.00201	CcSEcCtD
Clodronate—Urticaria—Methylprednisolone—multiple sclerosis	0.000371	0.00201	CcSEcCtD
Clodronate—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000369	0.002	CcSEcCtD
Clodronate—Decreased appetite—Dexamethasone—multiple sclerosis	0.000369	0.002	CcSEcCtD
Clodronate—Decreased appetite—Betamethasone—multiple sclerosis	0.000369	0.002	CcSEcCtD
Clodronate—Nausea—Mitoxantrone—multiple sclerosis	0.000368	0.00199	CcSEcCtD
Clodronate—Infection—Prednisone—multiple sclerosis	0.000367	0.00199	CcSEcCtD
Clodronate—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000366	0.00198	CcSEcCtD
Clodronate—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000366	0.00198	CcSEcCtD
Clodronate—SLC25A4—Disease—RPL5—multiple sclerosis	0.000366	0.00288	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCR2—multiple sclerosis	0.00036	0.00283	CbGpPWpGaD
Clodronate—Skin disorder—Prednisone—multiple sclerosis	0.000359	0.00194	CcSEcCtD
Clodronate—SLC25A6—Disease—CD28—multiple sclerosis	0.000359	0.00282	CbGpPWpGaD
Clodronate—Anorexia—Prednisone—multiple sclerosis	0.000352	0.00191	CcSEcCtD
Clodronate—SLC25A4—Disease—SLC11A1—multiple sclerosis	0.000351	0.00276	CbGpPWpGaD
Clodronate—Anaemia—Methotrexate—multiple sclerosis	0.00035	0.00189	CcSEcCtD
Clodronate—SLC25A5—Metabolism—BCHE—multiple sclerosis	0.000343	0.0027	CbGpPWpGaD
Clodronate—PTGS2—Overview of nanoparticle effects—IL6—multiple sclerosis	0.00034	0.00267	CbGpPWpGaD
Clodronate—Urticaria—Dexamethasone—multiple sclerosis	0.000337	0.00182	CcSEcCtD
Clodronate—Urticaria—Betamethasone—multiple sclerosis	0.000337	0.00182	CcSEcCtD
Clodronate—Abdominal pain—Dexamethasone—multiple sclerosis	0.000335	0.00181	CcSEcCtD
Clodronate—Abdominal pain—Betamethasone—multiple sclerosis	0.000335	0.00181	CcSEcCtD
Clodronate—Pruritus—Triamcinolone—multiple sclerosis	0.000331	0.00179	CcSEcCtD
Clodronate—Pruritus—Methylprednisolone—multiple sclerosis	0.00033	0.00179	CcSEcCtD
Clodronate—Dyspepsia—Prednisone—multiple sclerosis	0.000325	0.00176	CcSEcCtD
Clodronate—Decreased appetite—Prednisone—multiple sclerosis	0.000321	0.00174	CcSEcCtD
Clodronate—Rash—Prednisolone—multiple sclerosis	0.000321	0.00173	CcSEcCtD
Clodronate—Dermatitis—Prednisolone—multiple sclerosis	0.00032	0.00173	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00032	0.00173	CcSEcCtD
Clodronate—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000319	0.00173	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL6—multiple sclerosis	0.000319	0.00251	CbGpPWpGaD
Clodronate—Infection—Methotrexate—multiple sclerosis	0.000307	0.00166	CcSEcCtD
Clodronate—SLC25A5—Disease—CD86—multiple sclerosis	0.000306	0.0024	CbGpPWpGaD
Clodronate—Nausea—Prednisolone—multiple sclerosis	0.000302	0.00163	CcSEcCtD
Clodronate—Pruritus—Dexamethasone—multiple sclerosis	0.0003	0.00162	CcSEcCtD
Clodronate—Pruritus—Betamethasone—multiple sclerosis	0.0003	0.00162	CcSEcCtD
Clodronate—Skin disorder—Methotrexate—multiple sclerosis	0.0003	0.00162	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	0.0003	0.00236	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CXCL10—multiple sclerosis	0.000299	0.00235	CbGpPWpGaD
Clodronate—Vomiting—Triamcinolone—multiple sclerosis	0.000297	0.00161	CcSEcCtD
Clodronate—Vomiting—Methylprednisolone—multiple sclerosis	0.000297	0.0016	CcSEcCtD
Clodronate—Rash—Triamcinolone—multiple sclerosis	0.000295	0.0016	CcSEcCtD
Clodronate—Dermatitis—Triamcinolone—multiple sclerosis	0.000295	0.00159	CcSEcCtD
Clodronate—Anorexia—Methotrexate—multiple sclerosis	0.000294	0.00159	CcSEcCtD
Clodronate—Rash—Methylprednisolone—multiple sclerosis	0.000294	0.00159	CcSEcCtD
Clodronate—Dermatitis—Methylprednisolone—multiple sclerosis	0.000294	0.00159	CcSEcCtD
Clodronate—Urticaria—Prednisone—multiple sclerosis	0.000294	0.00159	CcSEcCtD
Clodronate—Abdominal pain—Prednisone—multiple sclerosis	0.000292	0.00158	CcSEcCtD
Clodronate—Diarrhoea—Betamethasone—multiple sclerosis	0.00029	0.00157	CcSEcCtD
Clodronate—Diarrhoea—Dexamethasone—multiple sclerosis	0.00029	0.00157	CcSEcCtD
Clodronate—SLC25A6—Metabolism of proteins—POMC—multiple sclerosis	0.000288	0.00227	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—BCHE—multiple sclerosis	0.000288	0.00226	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—CCL2—multiple sclerosis	0.000282	0.00222	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD28—multiple sclerosis	0.00028	0.0022	CbGpPWpGaD
Clodronate—Nausea—Triamcinolone—multiple sclerosis	0.000278	0.0015	CcSEcCtD
Clodronate—Nausea—Methylprednisolone—multiple sclerosis	0.000277	0.0015	CcSEcCtD
Clodronate—Dyspnoea—Methotrexate—multiple sclerosis	0.000275	0.00149	CcSEcCtD
Clodronate—Dyspepsia—Methotrexate—multiple sclerosis	0.000272	0.00147	CcSEcCtD
Clodronate—SLC25A5—Disease—CCR5—multiple sclerosis	0.000271	0.00213	CbGpPWpGaD
Clodronate—Vomiting—Betamethasone—multiple sclerosis	0.00027	0.00146	CcSEcCtD
Clodronate—Vomiting—Dexamethasone—multiple sclerosis	0.00027	0.00146	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—BDNF—multiple sclerosis	0.000269	0.00211	CbGpPWpGaD
Clodronate—Decreased appetite—Methotrexate—multiple sclerosis	0.000269	0.00145	CcSEcCtD
Clodronate—Rash—Betamethasone—multiple sclerosis	0.000268	0.00145	CcSEcCtD
Clodronate—Rash—Dexamethasone—multiple sclerosis	0.000268	0.00145	CcSEcCtD
Clodronate—Dermatitis—Dexamethasone—multiple sclerosis	0.000267	0.00145	CcSEcCtD
Clodronate—Dermatitis—Betamethasone—multiple sclerosis	0.000267	0.00145	CcSEcCtD
Clodronate—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000267	0.00144	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	0.000266	0.00209	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HLA-A—multiple sclerosis	0.000264	0.00208	CbGpPWpGaD
Clodronate—Pruritus—Prednisone—multiple sclerosis	0.000261	0.00141	CcSEcCtD
Clodronate—SLC25A6—Disease—CD86—multiple sclerosis	0.000256	0.00201	CbGpPWpGaD
Clodronate—Diarrhoea—Prednisone—multiple sclerosis	0.000253	0.00137	CcSEcCtD
Clodronate—Nausea—Betamethasone—multiple sclerosis	0.000252	0.00136	CcSEcCtD
Clodronate—Nausea—Dexamethasone—multiple sclerosis	0.000252	0.00136	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000251	0.00197	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL4—multiple sclerosis	0.00025	0.00196	CbGpPWpGaD
Clodronate—SLC25A5—Disease—APOE—multiple sclerosis	0.000247	0.00194	CbGpPWpGaD
Clodronate—Urticaria—Methotrexate—multiple sclerosis	0.000245	0.00133	CcSEcCtD
Clodronate—Abdominal pain—Methotrexate—multiple sclerosis	0.000244	0.00132	CcSEcCtD
Clodronate—Vomiting—Prednisone—multiple sclerosis	0.000235	0.00127	CcSEcCtD
Clodronate—Rash—Prednisone—multiple sclerosis	0.000233	0.00126	CcSEcCtD
Clodronate—Dermatitis—Prednisone—multiple sclerosis	0.000233	0.00126	CcSEcCtD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000229	0.0018	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000229	0.0018	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000228	0.00179	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CCR5—multiple sclerosis	0.000227	0.00178	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—POMC—multiple sclerosis	0.000225	0.00177	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—BCHE—multiple sclerosis	0.000225	0.00176	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000224	0.00176	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CD80—multiple sclerosis	0.000223	0.00175	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000223	0.00175	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HLA-A—multiple sclerosis	0.000221	0.00174	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—CCL2—multiple sclerosis	0.00022	0.00173	CbGpPWpGaD
Clodronate—Nausea—Prednisone—multiple sclerosis	0.00022	0.00119	CcSEcCtD
Clodronate—Pruritus—Methotrexate—multiple sclerosis	0.000219	0.00118	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000218	0.00171	CbGpPWpGaD
Clodronate—Diarrhoea—Methotrexate—multiple sclerosis	0.000211	0.00114	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000209	0.00164	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000207	0.00163	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TLR4—multiple sclerosis	0.000207	0.00163	CbGpPWpGaD
Clodronate—SLC25A6—Disease—APOE—multiple sclerosis	0.000207	0.00162	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—APOE—multiple sclerosis	0.000206	0.00162	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD86—multiple sclerosis	0.0002	0.00157	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—ICAM1—multiple sclerosis	0.000198	0.00156	CbGpPWpGaD
Clodronate—Vomiting—Methotrexate—multiple sclerosis	0.000196	0.00106	CcSEcCtD
Clodronate—Rash—Methotrexate—multiple sclerosis	0.000195	0.00105	CcSEcCtD
Clodronate—Dermatitis—Methotrexate—multiple sclerosis	0.000195	0.00105	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	0.000194	0.00153	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	0.000191	0.0015	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	0.000191	0.0015	CbGpPWpGaD
Clodronate—SLC25A5—Disease—TYK2—multiple sclerosis	0.000188	0.00148	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CD80—multiple sclerosis	0.000187	0.00147	CbGpPWpGaD
Clodronate—Nausea—Methotrexate—multiple sclerosis	0.000183	0.000992	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000183	0.00144	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	0.000177	0.00139	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—POMC—multiple sclerosis	0.000177	0.00139	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CCR5—multiple sclerosis	0.000177	0.00139	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—APOE—multiple sclerosis	0.000173	0.00136	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HLA-A—multiple sclerosis	0.000173	0.00136	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CD4—multiple sclerosis	0.00017	0.00134	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	0.00017	0.00134	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—ALB—multiple sclerosis	0.000162	0.00127	CbGpPWpGaD
Clodronate—SLC25A4—Disease—APOE—multiple sclerosis	0.000161	0.00127	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TYK2—multiple sclerosis	0.000158	0.00124	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000156	0.00123	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	0.000151	0.00119	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—POMC—multiple sclerosis	0.000149	0.00117	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD80—multiple sclerosis	0.000146	0.00115	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SRM—multiple sclerosis	0.000145	0.00114	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CD4—multiple sclerosis	0.000143	0.00112	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	0.000138	0.00108	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ALB—multiple sclerosis	0.000136	0.00106	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—APOE—multiple sclerosis	0.000135	0.00106	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	0.000135	0.00106	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	0.000134	0.00105	CbGpPWpGaD
Clodronate—SLC25A5—Disease—STAT3—multiple sclerosis	0.000132	0.00104	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	0.000127	0.000997	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	0.000123	0.00097	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TYK2—multiple sclerosis	0.000123	0.000967	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MYC—multiple sclerosis	0.000122	0.000962	CbGpPWpGaD
Clodronate—SLC25A5—Disease—TGFB1—multiple sclerosis	0.000122	0.00096	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MAPK1—multiple sclerosis	0.00012	0.000941	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—POMC—multiple sclerosis	0.000116	0.000912	CbGpPWpGaD
Clodronate—PTGS2—Disease—GPC5—multiple sclerosis	0.000111	0.000875	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CD4—multiple sclerosis	0.000111	0.000875	CbGpPWpGaD
Clodronate—SLC25A6—Disease—STAT3—multiple sclerosis	0.00011	0.000868	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—ALB—multiple sclerosis	0.000106	0.000831	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	0.000105	0.000824	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	0.000105	0.000822	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MYC—multiple sclerosis	0.000103	0.000806	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	0.000103	0.000806	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TGFB1—multiple sclerosis	0.000102	0.000804	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP27B1—multiple sclerosis	0.000102	0.000801	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP24A1—multiple sclerosis	0.000102	0.000801	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MAPK1—multiple sclerosis	0.0001	0.000789	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	9.97e-05	0.000783	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	9.96e-05	0.000783	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	9.76e-05	0.000767	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—GPC5—multiple sclerosis	9.33e-05	0.000733	CbGpPWpGaD
Clodronate—SLC25A5—Disease—IL6—multiple sclerosis	9.2e-05	0.000723	CbGpPWpGaD
Clodronate—SLC25A4—Disease—STAT3—multiple sclerosis	8.62e-05	0.000677	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MYC—multiple sclerosis	8.01e-05	0.000629	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TGFB1—multiple sclerosis	7.99e-05	0.000628	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	7.88e-05	0.000619	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MAPK1—multiple sclerosis	7.84e-05	0.000616	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—RRM1—multiple sclerosis	7.73e-05	0.000607	CbGpPWpGaD
Clodronate—SLC25A6—Disease—IL6—multiple sclerosis	7.71e-05	0.000606	CbGpPWpGaD
Clodronate—PTGS2—Disease—RPL5—multiple sclerosis	7.24e-05	0.000569	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	7.13e-05	0.00056	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	7.11e-05	0.000559	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	6.98e-05	0.000548	CbGpPWpGaD
Clodronate—PTGS2—Disease—SLC11A1—multiple sclerosis	6.94e-05	0.000545	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	6.64e-05	0.000522	CbGpPWpGaD
Clodronate—SLC25A4—Disease—IL6—multiple sclerosis	6.02e-05	0.000473	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6e-05	0.000471	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD28—multiple sclerosis	5.54e-05	0.000435	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.15e-05	0.000405	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.7e-05	0.000369	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—BCHE—multiple sclerosis	4.44e-05	0.000349	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD86—multiple sclerosis	3.95e-05	0.000311	CbGpPWpGaD
Clodronate—PTGS2—Disease—CCR5—multiple sclerosis	3.5e-05	0.000275	CbGpPWpGaD
Clodronate—PTGS2—Disease—HLA-A—multiple sclerosis	3.42e-05	0.000268	CbGpPWpGaD
Clodronate—PTGS2—Disease—APOE—multiple sclerosis	3.19e-05	0.000251	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD80—multiple sclerosis	2.88e-05	0.000227	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—APOE—multiple sclerosis	2.67e-05	0.00021	CbGpPWpGaD
Clodronate—PTGS2—Disease—TYK2—multiple sclerosis	2.43e-05	0.000191	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—POMC—multiple sclerosis	2.29e-05	0.00018	CbGpPWpGaD
Clodronate—PTGS2—Disease—CD4—multiple sclerosis	2.2e-05	0.000173	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ALB—multiple sclerosis	2.09e-05	0.000164	CbGpPWpGaD
Clodronate—PTGS2—Disease—STAT3—multiple sclerosis	1.7e-05	0.000134	CbGpPWpGaD
Clodronate—PTGS2—Disease—MYC—multiple sclerosis	1.58e-05	0.000124	CbGpPWpGaD
Clodronate—PTGS2—Disease—TGFB1—multiple sclerosis	1.58e-05	0.000124	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAPK1—multiple sclerosis	1.55e-05	0.000122	CbGpPWpGaD
Clodronate—PTGS2—Disease—IL6—multiple sclerosis	1.19e-05	9.35e-05	CbGpPWpGaD
